SUVEN Life Sciences Ltd

Communication to investors
September 2016

24-Nov-16

2016-17 Q2 results

Risk statement
Except for historical information, all of the statements, expectations
and assumptions, including expectations and assumptions,
contained in this presentation may be forward-looking statements
that involve a number of risks and uncertainties. Although Suven
attempts to be accurate in making these forward-looking statements,
it is possible that future circumstances might differ from the
assumptions on which such statements are based. Other important
factors which could cause these statements to differ materially
including outsourcing trends, economic conditions, dependence on
collaborative programs, retention of key personnel, technological
advances and continued success in growth of sales that may make
our products/services offerings less competitive; Suven may not
undertake to update any forward-looking statements that may be
made from time to time.
24-Nov-16

2016-17 Q2 results

FINANCIAL QUICK VIEW

FY 2016-17
FY 2016-17
Q2 to Q1 YoY (6 months)
Growth in revenue

-11.20%

13.42%

Growth in PAT

-18.54%

29.15%

Growth in EBIDTA

-8.96%

34.88%

Growth in Pre-R&D EBIDTA

-6.92%

22.27%

Increase in R&D Costs

-0.25%

-5.34%

R&D to sales

11.98%

11.28%

24-Nov-16

2016-17 Q2 results

MAJOR PROFITABILITY RATIOS

24-Nov-16

Q2 Sep 16

HY Sep 16

PAT to Income

21.62%

22.65%

EBIDTA to
Income

35.68%

35.21%

Cash Flow to
Income

25.44%

26.34%

Pre-R&D EBITDA
to Income

47.66%

46.50%

2016-17 Q2 results

Q2 to Q1 COMPARISON
Revenue - INR Million
1,500.00
1,300.00
1,100.00
900.00
700.00
500.00
300.00
100.00

1,377.24
1,223.05

400.00

324.63
264.44

300.00
200.00
100.00
Q1 Jun 16
Q1 Jun 16

Pre-R&D EBIDTA - INR Million

680.00

479.31
436.36

450.00

Q2 Sep 16

Q2 Sep 16

EBIDTA - INR Million

550.00

PAT - INR Million

626.21

582.90

580.00
480.00

350.00

380.00
250.00

280.00

150.00

180.00

50.00

80.00
Q1 Jun 16

24-Nov-16

Q1 Jun 16

Q2 Sep 16

2016-17 Q2 results

Q2 Sep 16

REVENUE COMPARISON
INR Million
3,000.00
2,600.29
2,500.00
2,292.66

2,000.00

1,500.00
1,229.50

1,223.05

Q2 Sep 15

Q2 Sep 16

1,000.00

500.00

24-Nov-16

HY Sep 15

2016-17 Q2 results

HY Sep 16

PAT COMPARISON
INR Million
700.00

589.07

600.00

500.00

456.13

400.00

300.00
251.24

264.44

200.00

100.00

Q2 Sep 15

24-Nov-16

Q2 Sep 16

HY Sep 15

2016-17 Q2 results

HY Sep 16

EBIDTA COMPARISON
INR Million
1,000.00
915.67
900.00
800.00
678.87

700.00
600.00
500.00
436.36
400.00

372.29

300.00
200.00
100.00
Q2 Sep 15

24-Nov-16

Q2 Sep 16

HY Sep 15

2016-17 Q2 results

HY Sep 16

R & D EXPENDITURE
INR Million
350.00
309.99
293.44

300.00

250.00

200.00

150.63

146.54

Q2 Sep 15

Q2 Sep 16

150.00

100.00

50.00

24-Nov-16

HY Sep 15

2016-17 Q2 results

HY Sep 16

PRE-R&D EBIDTA
INR Million
1,400.00
1,209.11
1,200.00

988.86

1,000.00

800.00

600.00

582.90
522.92

400.00

200.00

Q2 Sep 15

24-Nov-16

Q2 Sep 16

HY Sep 15

2016-17 Q2 results

HY Sep 16

PRE-R&D CASHFLOW
INR Million
1,200.00

978.35

1,000.00
842.41
800.00

600.00
447.98

457.63

Q2 Sep 15

Q2 Sep 16

400.00

200.00

24-Nov-16

HY Sep 15

2016-17 Q2 results

HY Sep 16

FINANCIAL SNAPSHOT
All figures are in INR Million, other than ratios and EPS

2016-17
Q2
Income
Pre-R&D EBITDA
Pre-R&D EBITDA
Margin
EBITDA
EBITDA Margin
EBIT
EBIT Margin
Financing costs
Taxes
Net Profit after tax
NP Margin
EPS (basic & diluted
not annualised)
Paid up share capital
(One Rupee Share)
Depreciation
R&D expenses

24-Nov-16

2016-17
Q1

Growth
%

1,223.05 1,377.24 -11.20%

582.90
626.21 -6.92%
47.66%
436.36
35.68%
390.84
31.96%
12.37
112.89
264.44
21.62%

45.47%
479.31 -8.96%
34.80%
431.25 -9.37%
31.31%
15.96
89.54
324.63 -18.54%
23.57%

2015-16
Q2
1,229.50
522.92
42.53%
372.29
30.28%
327.31
26.62%
15.08
59.87
251.24
20.43%

Growth
%
-0.52%
11.47%

17.21%
19.41%

5.25%

2016-17
HY

2015-16
HY

2,600.29
1,209.11

2,292.66
988.86

46.50%
915.67
35.21%
822.09
31.62%
28.33
202.43
589.07
22.65%

43.13%
678.87
29.61%
604.85
26.38%
25.42
121.03
456.13
19.90%

2.09

2.56

1.98

4.65

3.60

127.28
45.52
146.54

127.28
48.06
146.90

127.28
44.98
150.63

127.28
93.58
293.44

127.28
74.03
309.99

-0.25%

2016-17 Q2 results

-2.72%

Growth
%
13.42%
22.27%

34.88%
35.92%

29.15%

-5.34%

News Release
During the period Suven secures 9 product patents covering India,
Japan, Hong Kong, Canada, Israel, Europe, China and Mexico.
Suven Life Sciences presented at Society for Neuroscience (SFN2016) San Diego, USA
Suven Life Sciences presented at Bio-Europe 2016 at Cologne,
Germany
Suven Life sciences presented at AAPS 2016 at Denver, USA
Suven Life Sciences presented at Jefferies Healthcare Conference
2016 in London, UK

24-Nov-16

2016-17 Q2 results